Marcy l'Etoile - bioMérieux issues a reminder that on January 24, 2012, it set and communicated its objectives for 2012 sales growth. The Company is targeting organic growth between 3-5% or 6-8% at constant exchange rates and including the recent acquisitions of AES and Argene. This objective is in line with the one that was set in its 2015 strategic plan communicated in 2010.
As part of its standard forecasting process, which is conducted yearly, the Company is examining the assumptions of its strategic plan for 2015.
bioMérieux's 2011 Results press release will be issued on March 13, 2012.